Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, t
Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
11:37am, Wednesday, 25'th Sep 2024
Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to Nov
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) an
GLP-1 demand is going to remain higher than supply for foreseeable future, says BMO's Evan Seigerman
05:59pm, Tuesday, 24'th Sep 2024
Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's CEO and the demand for weight-loss drugs.
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC.
08:46am, Tuesday, 24'th Sep 2024
SAFETY HARBOR, Fla. , Sept. 24, 2024 /PRNewswire/ --- Integrated Ventures Inc. ("Company", "OTCQB: INTV") is pleased to announce that its newly launched subsidiary, MedWell USA, LLC has signed a strat
Life Time to Host Complimentary GLP-1, Weight Loss Livestream Event with Chief Science Officer and Experts September 25
03:25pm, Monday, 23'rd Sep 2024
Educational panel available for free via the Life Time App 6:00-7:30 p.m. CT CHANHASSEN, Minn.
Biotech stock plays outside of GLP-1 weight-loss market
06:35pm, Thursday, 19'th Sep 2024
BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 weight-loss space. The sky-high demand
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innova
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
10:07am, Wednesday, 18'th Sep 2024
Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill. The results looked better than those from a key rival.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform committed to breaking down barriers to safe and affordable healthcare
Northern Tool + Equipment Announces Partnership with Monster Jam®: Includes a Monster Jam Mini Build with Texas High School Students
02:57pm, Tuesday, 17'th Sep 2024
The partnership also makes Northern Tool + Equipment the official hardware retailer of tools and related equipment partner for Monster Jam BURNSVILLE, Minn., Sept. 17, 2024 /PRNewswire/ -- Northern To
- ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once-monthly subcutaneously and once-daily orally to treat obesity - ASC30 is two- to threefold more pot
Hims & Hers: Fear Surrounding GLP-1 Provides Another Opportunity
09:32am, Monday, 16'th Sep 2024
Hims & Hers' stock decline after GLP-1 concerns is an overreaction, presenting a strong investment opportunity. Management's consistent outperformance and strategic leadership, including key hires, bo
Becton, Dickinson and Company: Future Benefit From GLP-1 Drug Delivery
10:03am, Friday, 13'th Sep 2024
I reiterate a 'Buy' rating for BDX with a fair value of $265 per share, driven by growth in GLP-1 drug delivery and the acquisition of Edwards Lifesciences' Critical Care. BDX's strong market position
